Population Pharmacokinetics of Imatinib in CML Patients in Iran

Population Pharmacokinetics of Imatinib in CML Patients in Iran

The purpose of this study is to determine population Pharmacokinetics and differences and variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients in Iranian population.

patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study then population pharmacokinetics parameters is determined.

Inclusion Criteria:

• patient in chronic phase of myeloid leukemia
• no liver and renal failure

Exclusion Criteria:

• multiple dug treatment
• previous treatment of interferon
• patients in blast or accelerated phase